Vijay K. Ramanan
YOU?
Author Swipe
View article: NCMP-29. The risk for cognitive impairment differs in male and female cancer survivors
NCMP-29. The risk for cognitive impairment differs in male and female cancer survivors Open
BACKGROUND Understanding long-term sequelae of cancer care is critical. Cognitive impairment is a common and disabling survivorship issue. Because sex influences tumor biology, therapy exposure, and dementia risk, we examined whether cance…
View article: Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition
Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition Open
Our non-APOE amyloid GRS, which appropriately includes variants associated with amyloid deposition in APOE ɛ4/ɛ2 noncarriers, may advance personalized prediction of genetic susceptibility to β-amyloid accumulation within the …
View article: Author Correction: Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies
Author Correction: Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies Open
View article: Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy
Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy Open
INTRODUCTION African American (AA) individuals are underrepresented in biomarker studies for Alzheimer's disease (AD). Biomarkers that reflect the heterogeneity of AD and achieve the greatest accuracy across populations are sorely needed. …
View article: Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance Open
INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients…
View article: Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study
Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study Open
Objective To compare iron deposition in the substantia nigra (SN) as measured with quantitative susceptibility mapping (QSM) on antemortem magnetic resonance imaging (MRI) between individuals with and without Lewy‐related pathology at auto…
View article: Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies
Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies Open
Dementia with Lewy bodies (DLB) frequently coexists with Alzheimer's disease pathology, yet the pattern of cortical microstructural injury and its relationship with amyloid, tau, and cerebrovascular pathologies remains unclear. We applied …
View article: Longitudinal Evolution of Posterior Cortical Atrophy
Longitudinal Evolution of Posterior Cortical Atrophy Open
This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among youn…
View article: Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia
Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia Open
INTRODUCTION Sex differences are apparent in neurodegenerative diseases but have not been comprehensively characterized in frontotemporal dementia (FTD). METHODS Participants included 337 adults with autosomal dominant FTD enrolled in the …
View article: Eligibility for donanemab trial in a population-based study of cognitive aging
Eligibility for donanemab trial in a population-based study of cognitive aging Open
View article: Amyloid Biomarker Discordance in Patients Evaluated for Anti‐Amyloid Therapy
Amyloid Biomarker Discordance in Patients Evaluated for Anti‐Amyloid Therapy Open
Background Evidence for abnormal amyloid‐β (Aβ) plaque accumulation is necessary prior to initiating anti‐amyloid therapy in early symptomatic Alzheimer’s disease (AD). While the clinical trials for lecanemab and related drugs utilized pos…
View article: Substantia nigra iron deposition in Lewy body disease: an MRI quantitative susceptibility mapping and neuropathology study
Substantia nigra iron deposition in Lewy body disease: an MRI quantitative susceptibility mapping and neuropathology study Open
Background Parkinson’s disease and dementia with Lewy bodies are characterized by abnormal iron deposition in the substantia nigra, which can be measured with quantitative susceptibility mapping (QSM) on MRI. However, neuropathologic valid…
View article: Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression
Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression Open
Background Limbic‐predominant age‐related TDP‐43 encephalopathy (LATE) is a neuropathologically‐defined disease, and it is frequently comorbid with Alzheimer’s disease neuropathological change (ADNC). However, the neurological syndrome ass…
View article: Older predicted age using AI EKG‐based age prediction is associated with higher Alzheimer’s disease neuropathologic change
Older predicted age using AI EKG‐based age prediction is associated with higher Alzheimer’s disease neuropathologic change Open
Background There is increasing need for noninvasive biomarkers of Alzheimer’s Disease (AD) neuropathologic change for early detection and intervention through risk‐factor modification and disease‐modifying therapies. One such biomarker is …
View article: Tau deposition is associated with neurite abnormalities in white matter tracts and cortical grey matter regions in dementia with Lewy bodies
Tau deposition is associated with neurite abnormalities in white matter tracts and cortical grey matter regions in dementia with Lewy bodies Open
Background Dementia with Lewy bodies (DLB) frequently co‐occurs with Alzheimer’s disease (AD) pathologies, exacerbating disease progression. Biophysical models of diffusion imaging data, such as Neurite Orientation Dispersion and Density I…
View article: Multimodal Genetic Analysis of Brain Amyloidosis
Multimodal Genetic Analysis of Brain Amyloidosis Open
Background Genome‐wide association studies (GWAS) in Alzheimer’s disease (AD) leveraging endophenotypes beyond case/control diagnosis, such as brain amyloid β pathology, have shown promise in identifying novel variants and understanding th…
View article: Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls
Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls Open
View article: Gene-Specific Effects on Brain Volume and Cognition of <i>TMEM106B</i> in Frontotemporal Lobar Degeneration
Gene-Specific Effects on Brain Volume and Cognition of <i>TMEM106B</i> in Frontotemporal Lobar Degeneration Open
We identified associations of TMEM106B with gray matter volume and cognition in the presence of GRN and C9orf72 pathogenic variants. The association of TMEM106B with outcomes of interest in presymptomatic GRN…
View article: CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET
CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET Open
Determining the genetic architecture of Alzheimer’s disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron…
View article: Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities
Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities Open
With full FDA approval and Centers for Medicare & Medicaid Services coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment or mild dement…
View article: Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays Open
INTRODUCTION We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p‐tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice. METHODS Clinical perfo…
View article: Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD)
Correction: Implementation of genomic medicine for rare disease in a tertiary healthcare system: Mayo Clinic Program for Rare and Undiagnosed Diseases (PRaUD) Open
View article: Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease Open
Importance Factors associated with clinical heterogeneity in Alzheimer disease (AD) lay along a continuum hypothesized to associate with tangle distribution and are relevant for understanding glial activation considerations in therapeutic …
View article: Gene specific effects on brain volume and cognition of<i>TMEM106B</i>in frontotemporal lobar degeneration
Gene specific effects on brain volume and cognition of<i>TMEM106B</i>in frontotemporal lobar degeneration Open
Background and Objectives TMEM106B has been proposed as a modifier of disease risk in FTLD-TDP, particularly in GRN mutation carriers. Furthermore, TMEM106B has been investigated as a disease modifier in the context of healthy aging and ac…
View article: Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies Open
Dementia with Lewy bodies (DLB) is a neurodegenerative condition often co-occurring with Alzheimer’s disease (AD) pathology. Characterizing white matter tissue microstructure using Neurite Orientation Dispersion and Density Imaging (NODDI)…
View article: Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration Open
Importance Frontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive…
View article: Longitudinal Free‐Water Changes in Dementia with Lewy Bodies
Longitudinal Free‐Water Changes in Dementia with Lewy Bodies Open
Background Diffusion‐weighted magnetic resonance imaging (dMRI) examines tissue microstructure integrity in vivo. Prior dementia with Lewy bodies (DLB) diffusion tensor imaging studies yielded mixed results. Objective We employed free‐wate…
View article: Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies Open
INTRODUCTION Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emis…
View article: Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals Open
BACKGROUND We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals. METHODS We studied 645 Mayo Clinic Study of Agin…
View article: Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes
Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes Open
We found that ML-PRS approaches improved upon standard PRS for prediction of AD endophenotypes, partly related to improved accounting for nonlinear effects of genetic susceptibility alleles. Further adaptations of the ML-PRS framework coul…